Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 21, 2020 - Issue 16
Submit an article Journal homepage
1,100
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluation

Ponesimod for the treatment of relapsing multiple sclerosis

Elisa Baldina Epidemiology and Biostatistics Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-3277-5623View further author information
ORCID Icon &
Alessandra Lugaresib Dipartimento di Scienze Biomediche e Neuromotorie, Università UOSI Riabilitazione Sclerosi Multipla, di Bologna, Bologna, Italy;c UOSI Riabilitazione Sclerosi Multipla, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2902-5589View further author information
ORCID Icon
Pages 1955-1964 | Received 23 Apr 2020, Accepted 20 Jul 2020, Published online: 18 Aug 2020

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Laura Dumitrescu, Athanasios Papathanasiou, Catalina Coclitu, Afagh Garjani, Nikos Evangelou, Cris S. Constantinescu, Bogdan Ovidiu Popescu & Radu Tanasescu. (2023) An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy 24:4, pages 495-509.
Read now
Victor Constantinescu, Katja Akgün & Tjalf Ziemssen. (2022) Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more. Expert Opinion on Drug Metabolism & Toxicology 18:10, pages 675-693.
Read now

Articles from other publishers (11)

Dnyandev G. Gadhave, Vrashabh V. Sugandhi & Chandrakant R. Kokare. (2024) Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: Multiple sclerosis. Brain Research 1822, pages 148674.
Crossref
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, Andrew C. Flick, Erick A. Lindsey, Simon Berritt, Daniel W. Carney, Jacob C. DeForest, Hong X. Ding, Sarah J. Fink, Tony S. Gibson, Kaitlyn Gray, Aran K. Hubbell, Amber M. Johnson, Yiyang Liu, Subham Mahapatra, Indrawan J. McAlpine, Rebecca B. Watson & Christopher J. O’Donnell. (2023) Synthetic Approaches to the New Drugs Approved During 2021. Journal of Medicinal Chemistry 66:15, pages 10150-10201.
Crossref
Amal Alnaif, Isabelle Oiler & Manoranjan S. D’Souza. (2022) Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis. Annals of Pharmacotherapy 57:8, pages 956-965.
Crossref
Faryal Chaudhry, Rubina Munir & Nayab Malik. (2023) N-Heterocycles as Privileged Scaffolds in FDA Approved Different NMEs of 2021: A Review. Letters in Organic Chemistry 20:4, pages 287-299.
Crossref
Lifan Xu, Peng Lu & Yubin Wang. (2022) Sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease and other immune-mediated diseases. Medicinal Chemistry Research 31:12, pages 2074-2088.
Crossref
Abhi Shah, Viraj Panchal, Kashyap Patel, Zainab Alimohamed, Nirja Kaka, Yashendra Sethi & Neil Patel. (2022) Pathogenesis and management of multiple sclerosis revisited. Disease-a-Month, pages 101497.
Crossref
Gary Álvarez Bravo, René Robles Cedeño, Marc Puig Casadevall & Lluís Ramió-Torrentà. (2022) Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. Cells 11:13, pages 2058.
Crossref
Ramya Talanki Manjunatha, Salma Habib, Sai Lahari Sangaraju, Daniela Yepez & Xavier A Grandes. (2022) Multiple Sclerosis: Therapeutic Strategies on the Horizon. Cureus.
Crossref
Jorge Correale, Mario Javier Halfon, Dominic Jack, Adrián Rubstein & Andrés Villa. (2021) Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Multiple Sclerosis and Related Disorders 56, pages 103264.
Crossref
Andrea M Kuczynski & Jiwon Oh. (2021) Ozanimod for the treatment of relapsing forms of multiple sclerosis. Neurodegenerative Disease Management 11:3, pages 207-220.
Crossref
Tobias Brummer, Tobias Ruck, Sven G. Meuth, Frauke Zipp & Stefan Bittner. (2021) Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Therapeutic Advances in Neurological Disorders 14, pages 175628642110355.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.